Safety of anti-malarial drugs in pregnancy must be monitored

Sep 09, 2008

There is an urgent need to develop systems to assess the safety of antimalarials in early pregnancy, says a new essay in this week's PLoS Medicine.

Feiko ter Kuile (Liverpool School of Tropical Medicine, Liverpool, UK) and colleagues report that the anti-malarial drugs artemisinins are effective and commonly used, but they have been shown to be toxic to embryos in animal models. Their safety in early human pregnancies remains uncertain, despite up to 10% of embryos being exposed to anti-malarial drugs in malaria endemic countries.

Because most of the approaches used in wealthier countries to evaluate a drug's toxicity in pregnancy do not apply in low income countries, the authors argue that we must establish an international antimalarial pregnancy exposure registry. This would enable a "targeted prospective pharmacovigilance approach and timely assessment of the risk–benefit profile of antimalarials," say ter Kuile and colleagues.

Source: Public Library of Science

Explore further: Risks of taking paracetamol long-term may have been underestimated by clinicians

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.